Cyteir Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2022 to Q3 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cyteir Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q3 2023.
  • Cyteir Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2023 was 4.4 %, a 20.9% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2023 4.4 -1.16 -20.9% Sep 30, 2023
Q2 2023 4.48 -0.83 -15.6% Jun 30, 2023
Q1 2023 4.87 +0.09 +1.88% Mar 31, 2023
Q4 2022 5.74 Dec 31, 2022
Q3 2022 5.56 Sep 30, 2022
Q2 2022 5.31 Jun 30, 2022
Q1 2022 4.78 Mar 31, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.